Since its approval by the US Food and Drug Administration in 2002, voriconazole has
become a key component in the successful treatment of many invasive fungal infections …

Pharmacists are uniquely qualified to play essential roles in the clinical implementation of
pharmacogenomics. However, specific responsibilities and resources needed for these …

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Background. Blood levels of voriconazole, a first line therapy for invasive aspergillosis, may
correlate with adverse events and treatment response. However, no randomized controlled …

Background During an infection or inflammation, several drug-metabolizing enzymes in the
liver are down-regulated, including cytochrome P450 iso-enzymes. Since voriconazole is …

The aim of this study was to determine an optimum voriconazole target concentration, to
study the influence of CYP2C19 gene status on metabolism of voriconazole and to identify a …

Background Voriconazole, a first-line antifungal drug, exhibits nonlinear pharmacokinetics
(PK), together with large interindividual variability but a narrow therapeutic range, and …

Administration of azole antifungals to tacrolimus-treated solid organ recipients results in a
major drug–drug interaction characterized by increased exposure to tacrolimus. The …

Objectives Voriconazole exhibits highly variable, non-linear pharmacokinetics and is
associated with a narrow therapeutic range. This study aimed to investigate the population …

Objectives The objective of this study was to estimate the population pharmacokinetics of
voriconazole, to identify the factors influencing voriconazole pharmacokinetics and to …